Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Status:
Active, not recruiting
Trial end date:
2026-10-15
Target enrollment:
Participant gender:
Summary
Phase II trial in which patients with metastatic solid tumors experiencing progression after
first line standard chemotherapy or for which there is no standard chemotherapy, and for
which pembrolizumab does not have an FDA or compendia listing approved indication, will
receive pembrolizumab intravenously at a dose of 200 mg every 3 weeks.